Faricimab — Discount Pricing
Faricimab is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Faricimab Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $254.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Faricimab
Faricimab is a prescription medication. Ask your doctor if Faricimab is right for you.
How to Check Faricimab Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Faricimab at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Ophthalmology
What Faricimab is approved for (FDA label)
VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.3 ) 1.1 Neovascular (wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Macular Edema Following Retinal Vein Occlusion (RVO)
Source: Read the full FDA label on DailyMed. Label effective date: April 15, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Faricimab (FDA label)
VABYSMO is a clear to opalescent, colorless to brownish-yellow solution available as: Injection: 6 mg (0.05 mL of 120 mg/mL solution) in a single-dose prefilled glass syringe Injection: 6 mg (0.05 mL of 120 mg/mL solution) in a single-dose glass vial Injection: 6 mg (0.05 mL of 120 mg/mL solution) in a single-dose prefilled syringe ( 3 ) Injection: 6 mg (0.05 mL of 120 mg/mL solution) in a single-dose vial ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 04cc9ef7-c02a-4e92-a655-0062674e8487. SPL document ID: d03c8813-cfdd-498f-9085-44e3d8436620. Label effective date: April 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Faricimab (FDA label)
The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4) ] Endophthalmitis and retinal detachments [see Warnings and Precautions (5.1) ] Increase in intraocular pressure [see Warnings and Precautions (5.2) ] Thromboembolic events [see Warnings and Precautions (5.3) ] Retinal Vasculitis and/or Retinal Vascular Occlusion [see Warnings and Precautions (5.4) ] The most common adverse reactions (≥ 5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: 04cc9ef7-c02a-4e92-a655-0062674e8487. SPL document ID: d03c8813-cfdd-498f-9085-44e3d8436620. Label effective date: April 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Faricimab (FDA label)
Ocular or periocular infection ( 4.1 ) Active intraocular inflammation ( 4.2 ) Hypersensitivity ( 4.3 ) 4.1 Ocular or Periocular Infections VABYSMO is contraindicated in patients with ocular or periocular infections. 4.2 Active Intraocular Inflammation VABYSMO is contraindicated in patients with active intraocular inflammation. 4.3 Hypersensitivity VABYSMO is contraindicated in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.
Source: FDA prescribing information (DailyMed). Set ID: 04cc9ef7-c02a-4e92-a655-0062674e8487. SPL document ID: d03c8813-cfdd-498f-9085-44e3d8436620. Label effective date: April 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.